5 research outputs found
Monographiae generis Polygoni prodromus
No full textauctore Carolo Friderico MeisnerHandschriftliches Exlibris: "Mr Robert Brown J. R. & L. S. respectfully from the author. Bern/Switzerland/March 30th 1827." Exemplar der ETH-BIB, Rar 2634
Monographiae generis Polygoni prodromus
No full textauctore Carolo Friderico MeisnerHandschriftliches Exlibris: "Mr Robert Brown J. R. & L. S. respectfully from the author. Bern/Switzerland/March 30th 1827." Exemplar der ETH-BIB, Rar 2634
Correction of cardiac output obtained by Modelflow® from finger pulse pressure profiles with a respiratory method in humans
No full textThe beat-by-beat non-invasive assessment of cardiac output (Q˙ , litre · min−1) based on the arterial pulse pressure analysis called Modelflow® can be a very useful tool for quantifying the cardiovascular adjustments occurring in exercising humans. ˙Q was measured in nine young subjects at rest and during steady-state cycling exercise performed at 50, 100, 150 and 200 Wby using Modelflow® applied to the Portapres® non-invasive pulse wave (˙QModelflow) and by means of the open-circuit acetylene uptake (˙QC2H2 ). ˙Q values were correlated linearly (r=0.784), but Bland–Altman analysis revealed that mean ˙QModelflow − ˙QC2H2 difference (bias) was equal to 1.83 litre · min−1 with an S.D. (precision) of 4.11 litre · min−1, and 95% limits of agreement were relatively large, i.e. from −6.23 to +9.89 litre · min−1. ˙QModelflow values were then multiplied by individual calibrating factors obtained by dividing ˙QC2H2 by ˙QModelflow for each subject measured at 150 Wto obtain corrected˙Q Modelflow (˙Qcorrected) values. ˙Qcorrected values were compared with the corresponding ˙QC2H2 values, with values at 150 Wignored. Data were correlated linearly (r=0.931) and were not significantly different. The bias and precision were found to be 0.24 litre · min−1 and 3.48 litre · min−1 respectively, and 95% limits of agreement ranged from −6.58 to +7.05 litre · min−1. In conclusion, after correction by an independent method, Modelflow® was found to be a reliable and accurate procedure for measuring ˙Q in humans at rest and exercise, and it can be proposed for routine purposes
Precisiones sobre los tipos de varios nombres de plantas descritas por Candolle
No full textThe respective “lectotypes” designated by Burdet and collaborators 1983 for the names Bellis pappulosa, Carduncellus hispanicus, Centaurea bombycina, Erigeron frigidus and Senecio quinqueradiatus (Compositae) are ineffective, being contrary to Art. 9.3 of the International Code of Nomenclature. These species were described by Augustin Pyramus de Candolle from material collected by Edmond Boissier, and the material used by the author and the herbarium where it is preserved is specified in their respective protologues. Specimens preserved at G-DC should be considered as holotypes for each of these names.Los respectivos “lectótipos” en el herbario G-BOIS designados por Burdet y colaboradores en 1983 para los nombres Bellis pappulosa, Carduncellus hispanicus, Centaurea bombycina, Erigeron frigidus y Senecio quinqueradiatus (Compositae) deben desestimarse ya que fueron designados en contra con lo dispuesto en el Art. 9.3 del Código Internacional de Nomenclatura. Estas especies fueron descritas por Augustin Pyramus de Candolle a patir de material recolectado por Edmond Boissier, en cuyos respectivos protólogos se especifica el material usado para las descripciones y el herbario donde está conservado. Especímenes conservados en el herbario G-DC deben considerarse como holótipos para cada uno de estos nombres
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
No full textObjective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified. © 2020 The Author
